Journey Medical Corporation reported that prescriptions for its Emrosi product reached 14,000 in July [1].
The growth indicates a strengthening market position for the company's primary product line as it scales operational efficiency and expands its insurance network.
During a virtual earnings call held on Wednesday, Aug. 12, the company detailed its financial performance for the second quarter [3]. Claude Maraoui, co-founder, president and CEO, and Jaclyn Jaffe, senior director of corporate operations, led the discussion regarding the company's trajectory.
Company data shows that Emrosi volume rose about 20% sequentially [2]. This increase in volume coincides with improved profit margins and a broader reach among payers, which allows more patients to access the treatment.
The company focused on these operational improvements to drive sustainable growth. By expanding payer coverage, Journey Medical aims to reduce barriers to prescription fulfillment, a key factor in the recent volume spike.
Executives said that the combination of higher volume and better margins reflects a more efficient corporate structure. The company continues to monitor these trends to ensure that the growth in July carries into the next quarter.
“Emrosi prescriptions reached 14,000 in July”
The sequential growth in Emrosi prescriptions suggests that Journey Medical is successfully navigating the transition from product launch to market penetration. By securing expanded payer coverage, the company is addressing the primary hurdle for specialty medical products: affordability and insurance reimbursement. If the 20% volume increase is sustained, it may signal a shift toward long-term profitability as higher margins offset initial operational costs.
